Hepatic Encephalopathy Treatment Market Size in the 7MM is expected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight's "Hepatic Encephalopathy Market Insights, Epidemiology and Market Forecast- 2034" report delivers an in-depth understanding of the Hepatic Encephalopathy, historical and forecasted epidemiology as well as the Hepatic Encephalopathy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Hepatic Encephalopathy Market Share @ https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Hepatic Encephalopathy Market Report
• In September 2025, Bausch Health Americas Inc. announced a phase 3 study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.
• The total Hepatic Encephalopathy diagnosed prevalent cases in the US are expected to increase with a significant CAGR by 2034, from around 209 thousand cases in 2023 in the US.
• Among the European countries, the UK (28%) had the highest diagnosed prevalent population of hepatic encephalopathy, followed by Germany in 2023. On the other hand, Spain had the least diagnosed prevalent population around 9% of Hepatic Encephalopathy in the same year.
• In Japan, among diagnosed prevalence cases of Hepatic Encephalopathy, most cases were of Covert Hepatic Encephalopathy (~17.7 thousand) in 2023. While Overt Hepatic Encephalopathy cases were around 11.8 thousand in the same year.
• The Hepatic Encephalopathy diagnosed cases were segmented based on age in seven age‐groups
• Assessments as per DelveInsight's analysts show that the majority of cases of Hepatic Encephalopathy are occupied by males as compared to females. There were approximately 152 thousand male and 57 thousand female cases of Hepatic Encephalopathy in 2023 in the US.
• The leading Hepatic Encephalopathy Companies such as Salix Pharmaceuticals, Bausch Health, Axcella Health, Inc., Umecrine Cognition, Vedanta Biosciences, Patricia Bloom, Rebiotix, and others.
• Promising Hepatic Encephalopathy Pipeline Therapies such as 25% IV albumin, VSL#3, Rifaximin SSD, AST-120, Lactulose and others.

Stay ahead in the Hepatic Encephalopathy Therapeutics Market with DelveInsight's Strategic Report @ https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hepatic Encephalopathy Epidemiology Segmentation in the 7MM
• Hepatic Encephalopathy Diagnosed Prevalent Cases
• Hepatic Encephalopathy Gender-specific Diagnosed Prevalent Cases
• Hepatic Encephalopathy Age-specific Diagnosed Prevalent Cases
• Hepatic Encephalopathy Type-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Hepatic Encephalopathy Epidemiology trends @ https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hepatic Encephalopathy Marketed Drugs
• Xifaxan (Rifaximin/OHE7): Salix Pharmaceuticals/Bausch Health
Xifaxan (rifaximin) tablets (550 mg) are indicated for the reduction in risk of Overt Hepatic Encephalopathy recurrence in patients ≥ 18 years of age. Rifaximin has been granted Orphan Drug designation by the FDA for use in hepatic encephalopathy. In addition, guidelines from the AASLD and EASL recommend rifaximin as an add-on therapy to lactulose to reduce the risk of OHE recurrence.

Hepatic Encephalopathy Emerging Drugs
• Golexanolone: Umecrine Cognition AB
Golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone. Golexanolone prevents the harmful effects induced by elevated levels of allopregnanolone in the brain. In contrast to traditional GABA-A antagonists, golexanolone can not completely block the receptor's function and thereby induce side effects such as seizures and unconsciousness. Golexanolone is currently under development for the treatment of two disorders - Primary Biliary Cholangitis (PBC) and Hepatic Encephalopathy.

To learn more about Hepatic Encephalopathy treatment guidelines, visit @ https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hepatic Encephalopathy Drugs Market Insights
The current Hepatic Encephalopathy therapeutics market landscape is dependent on the use of medications. Common medications which are used in the management of HE in the United States include lactulose and rifaximin. Nutrition may also play a key role in managing HE and preventing a recurrence. The second line, less accepted therapies, include probiotics, branched-chain amino acids (BCAAs), flumazenil, zinc, and ammonia scavengers. Other agents that are used include oral antibiotics (neomycin, metronidazole, and rifaximin) that can reduce urease-producing bacteria in the intestines, resulting in a decrease in ammonia production and absorption through the gastrointestinal tract. Both neomycin and metronidazole have been used for many years to treat HE and are inexpensive.

Hepatic Encephalopathy Market Outlook
The current Hepatic Encephalopathy treatment involves reducing ammonia levels, which is the central therapeutic strategy. This can be achieved through various interventions, including dietary protein supplementation, purgatives such as nonabsorbable disaccharides and enemas, nonabsorbable antibiotics, modulation of interorgan ammonia using L-ornithine, L-aspartate (LOLA), sodium benzoate, and phenylacetate, and others like flumazenil, bromocriptine, acarbose, probiotics, and emerging therapies like LOLA, sodium benzoate, and acetyl L-carnitine.

Learn more about the FDA-approved drugs for Hepatic Encephalopathy @ https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Hepatic Encephalopathy Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Hepatic Encephalopathy Companies- Salix Pharmaceuticals, Bausch Health, Axcella Health, Inc., Umecrine Cognition, Vedanta Biosciences, Patricia Bloom, Rebiotix, and others.
• Hepatic Encephalopathy Pipeline Therapies- 25% IV albumin, VSL#3, Rifaximin SSD, AST-120, Lactulose and others.
• Hepatic Encephalopathy Therapeutic Assessment: Hepatic Encephalopathy current marketed and Hepatic Encephalopathy emerging therapies
• Hepatic Encephalopathy Market Dynamics: Hepatic Encephalopathy market drivers and Hepatic Encephalopathy market barriers
• Hepatic Encephalopathy Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Hepatic Encephalopathy Unmet Needs, KOL's views, Analyst's views, Hepatic Encephalopathy Market Access and Reimbursement

Table of Content
1. Key Insights
2. Report Introduction
3. Hepatic Encephalopathy Market Overview at a Glance
4. Epidemiology and Market Forecast Methodology of Hepatic Encephalopathy
5. Executive Summary of Hepatic Encephalopathy
6. Key Events
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Drugs
11. Emerging Drugs
12. Hepatic Encephalopathy: Seven Major Market Analysis
13. KOL Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.